By informing pharmacologic and genetic experiments in subtype-matched GBM organoids, SPHINKS-MK delivered PKCδ and DNA-PKcs as experimentally validated MKs for the aggressive GPM and PPR subtypes of GBM. This evidence concerns the gene PRKCD and glioblastoma.